Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed specifically for newborns and ...

A handout image made available by the National Oceanography Centre on July 24, 2023, shows a carnivorous sponge, Axoniderma mexicana, photographed during a recent ...

The global burden of malaria remains significant, with an estimated 241 million cases and 627,000 deaths reported annually. This ongoing crisis calls for ...

Novartis (www.Novartis.com) has delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999; With other innovations, the Novartis ...

Antimalarial drug resistance is a pressing issue in combating the spread of malaria worldwide. In a new study, researchers discovered a key process where malarial parasites take up a human blood cell ...

Malaria in pregnancy can seriously harm both the mother and the unborn baby, especially if the infection is not treated early ...

GENEVA — Switzerland's medical products authority has granted the first approval for a malaria medicine designed for small infants, touted as an advance against a disease that takes hundreds of ...

​The newly prequalified treatment—artemether-lumefantrine — is the first antimalarial formulation designed specifically for ...

Lupus nephritis has a high burden of kidney and non-kidney damage accrual due to persistent disease activity, treatment-related toxicity, and age-related factors.

Malaria outbreaks are rising again in parts of southern Africa. Across the SADC (Southern African Development Community) ...